Horizon Pharma Agrees to Buy Vidara Sending Shares Higher
This article is for subscribers only.
Horizon Pharma Inc., maker of treatments for arthritis, pain and inflammatory diseases, agreed to purchase Ireland’s Vidara Therapeutics International Ltd. for about $660 million, sending shares to their highest value ever.
The combined company, to be renamed Horizon Pharma Plc, will be based in Ireland to provide a “tax-efficient corporate structure,” Deerfield, Illinois-based Horizon said in a statement today. The new company’s tax rate is expected to be a percentage in the low 20s or less, compared with a rate in the high 30s for Horizon as a stand-alone entity, according to a regulatory filing.